NewBridge Global Ventures, Inc., through its subsidiaries, cultivates, manufactures, and distributes medical and recreational cannabis products in California.
+ 2 more risks
Overvalued with worrying balance sheet.
Share Price & News
How has NewBridge Global Ventures's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NBGV's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: NBGV underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.
Return vs Market: NBGV underperformed the US Market which returned 18.7% over the past year.
Price Volatility Vs. Market
How volatile is NewBridge Global Ventures's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is NewBridge Global Ventures undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NBGV's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NBGV's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NBGV is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: NBGV is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NBGV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NBGV is good value based on its PB Ratio (1x) compared to the US Pharmaceuticals industry average (3.2x).
How is NewBridge Global Ventures forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NewBridge Global Ventures has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of NBGV’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access NewBridge Global Ventures's filings and announcementshere.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has NewBridge Global Ventures performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: NBGV is currently unprofitable.
Growing Profit Margin: NBGV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NBGV's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NBGV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NBGV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.1%).
Return on Equity
High ROE: NBGV has a negative Return on Equity (-78.17%), as it is currently unprofitable.
How is NewBridge Global Ventures's financial position?
Financial Position Analysis
Short Term Liabilities: NBGV's short term assets ($491.4K) do not cover its short term liabilities ($8.5M).
Long Term Liabilities: NBGV's short term assets ($491.4K) do not cover its long term liabilities ($1.5M).
Debt to Equity History and Analysis
Debt Level: NBGV's debt to equity ratio (35.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if NBGV's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if NBGV has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NBGV has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is NewBridge Global Ventures's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NBGV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NBGV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NBGV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NBGV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NBGV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Chris Bourdon serves as Chairman and Chief Executive officer of NewBridge Global Ventures, Inc. since October 16, 2019. Mr. Bourdon is Founder, Managing Director and Managing Partner of The Last90. He ...
|Chairman & CEO||0.83yr||no data||no data|
|Interim Chief Technology Officer||0.83yr||no data||no data|
|Chief Compliance Officer||1.67yrs||no data||0.45% |
|Senior Vice President of Corporate Development||no data||no data||no data|
|Chief Strategy Officer||1yr||no data||no data|
|Corporate Controller||1.58yrs||no data||no data|
|Secretary||2.5yrs||no data||0.044% |
Experienced Management: NBGV's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|Chairman & CEO||0.83yr||no data||no data|
|Director||0.83yr||no data||no data|
|Director||1.17yrs||no data||13.46% |
|Director||0.50yr||no data||no data|
Experienced Board: NBGV's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.8%.
NewBridge Global Ventures, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: NewBridge Global Ventures, Inc.
- Ticker: NBGV
- Exchange: OTCPK
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$14.597m
- Shares outstanding: 73.72m
- Website: https://www.newbridgegv.com
Number of Employees
- NewBridge Global Ventures, Inc.
- 2545 Santa Clara Avenue
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NBGV||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Jul 2018|
NewBridge Global Ventures, Inc., through its subsidiaries, cultivates, manufactures, and distributes medical and recreational cannabis products in California. It also offers consulting services to cultivat ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/14 12:32|
|End of Day Share Price||2020/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.